In Reply
- PMID: 40924409
- DOI: 10.1097/AOG.0000000000005968
In Reply
Conflict of interest statement
Financial Disclosure The authors did not report any potential conflicts of interest.
References
-
- Yuk JS, Kim MH, Yoon SH, Han GH, Noh JH. Association between levonorgestrel-releasing intrauterine system exposure duration and breast cancer incidence. Obstet Gynecol 2025;145:523–31. doi: 10.1097/AOG.0000000000005881 - DOI
-
- Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast cancer in users of levonorgestrel-releasing intrauterine systems. JAMA 2024;332:1578–80. doi: 10.1001/jama.2024.18575 - DOI
-
- Lim WH. Breast cancer and levonorgestrel-releasing intrauterine systems [letter]. JAMA 2025;333:1176. doi: 10.1001/jama.2024.27807 - DOI
-
- Nabila S, Choi JY, Abe SK, Islam MR, Rahman MS, Saito E, et al. Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan, and Korea. Breast Cancer Res 2024;26:15. doi: 10.1186/s13058-024-01766-0 - DOI
-
- Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond) 2021;41:1183–94. doi: 10.1002/cac2.12207 - DOI
LinkOut - more resources
Full Text Sources
